Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma-Reference-Cited by-同舟云学术

Association of Baseline Serum Levels of CXCL5 With the Efficacy of Nivolumab in Advanced Melanoma

Published:2019-04-26 Issue: Volume:6 Page:
ISSN:2296-858X
Container-title:Frontiers in Medicine
language:
Short-container-title:Front. Med.

Author:

Fujimura Taku,Sato Yota,Tanita Kayo,Lyu Chunbing,Kambayashi Yumi,Amagai Ryo,Otsuka Atsushi,Fujisawa Yasuhiro,Yoshino Koji,Matsushita Shigeto,Uchi Hiroshi,Yamamoto Yuki,Hata Hiroo,Funakoshi Takeru,Nonomura Yumi,Tanaka Ryota,Okuhira Hisako,Wada Naoko,Hashimoto Akira,Aiba Setsuya

Publisher

Frontiers Media SA

Subject

General Medicine

Reference33 articles.

1. Overall survival with combined nivolumab and ipilimumab in advanced melanoma;Wolchok;N Engl J Med.,2017

2. Nivolumab in previously untreated melanoma without BRAF mutation;Robert;N Engl J Med.,2015

3. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis;Tarhini;Immunotherapy.,2018

4. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med.,2015

5. Whole-genome landscapes of major melanoma subtypes;Hayward;Nature.,2017

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma;Frontiers in Oncology;2024-05-15

2. Immunotherapy in melanoma: Can we predict response to treatment with circulating biomarkers?;Pharmacology & Therapeutics;2024-04

3. Serum CCL22 Increased in Advanced Melanoma Patients with Liver Metastases: Report of 5 Cases;Case Reports in Oncology;2022-12-27

4. Immunotherapy for Melanoma: The Significance of Immune Checkpoint Inhibitors for the Treatment of Advanced Melanoma;International Journal of Molecular Sciences;2022-12-11

5. Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment;Liver Cancer;2022-10-31